Pulmonary Hypertension and Venous Thrombosis-embolic Disease
When it comes to pulmonary hypertension and venous thrombo-embolic (VTE) disease, the year has been filled with controversial topics and issues lacking clear evidence to finalize care decisions. The Pulmonary Hypertension and VTE Learning Pathway at ACC.17 selects many of these topics and opens them up for debate and discussion by panelists and international experts and provides attendees with question and answer opportunities.
Hot Topics and Great Debates in Pulmonary Hypertension (session #618) provides a great example of what you can expect in the Pulmonary Hypertension and VTE Learning Pathway with debates on these everyday questions:
- With the publication of recent trials, where does upfront combination therapy belong in our everyday management?
- With the recent publication of conflicting registry data on anticoagulation, where does this belong in everyday management?
- Left heart and lung disease etiologies seem more prevalent than group 1 PAH; what’s the approach for these patients?
Find out more about the efforts of the National Institutes of Health and others regarding personalized medicine in treating pulmonary vascular disease in session #634, The OMICS in Pulmonary Hypertension.
Multidisciplinary pulmonary embolism response teams (PERTs) are cropping up across the country. Hear from the multiple specialists on a PERT team as they provide their viewpoints on tackling acute pulmonary embolism in Multi-Disciplinary Care for Acute Pulmonary Embolism: The PE Response Team (PERT) Model (session #775).
Join us for ACC.17 to hear and participate in these debates that may help to clarify controversies or answer pending questions on how to provide the best care for patients with these conditions.
| 2017 American College of Cardiology Foundation. Visit ACC.org|